Editas Medicine CMO Baisong Mei steps down; separation terms outlined

Editas Medicine, Inc.

Baisong Mei to step down as CMO effective Dec 31, 2024; transition period ends Jan 31, 2025.
Separation agreement provides 12 months base salary, COBRA contributions, and potential 2024 bonus.
Vested stock option exercise extended to Dec 31, 2025; unvested RSUs vest through 90 days post-separation.
Agreement includes standard release, non-disparagement, and confidentiality clauses.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.